• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Nuvo Subsidiary Obtains Rights to Resultz

    Bryan Mc Govern
    Jan. 15, 2018 09:29AM PST
    Pharmaceutical Investing

    Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced its Ireline subsidiary acquired the U.S. rights of Resultz from Piedmont Pharmaceuticals. As quoted in the press release: The acquisition includes all U.S. product and intellectual property rights and is a complementary follow-on to Nuvo’s acquisition of the global, ex-U.S. Resultz product rights announced on January 2, 2018.  Nuvo now owns all Resultz product …

    Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced its Ireline subsidiary acquired the U.S. rights of Resultz from Piedmont Pharmaceuticals.
    As quoted in the press release:

    The acquisition includes all U.S. product and intellectual property rights and is a complementary follow-on to Nuvo’s acquisition of the global, ex-U.S. Resultz product rights announced on January 2, 2018.  Nuvo now owns all Resultz product and intellectual property rights throughout the world.
    “We are thrilled to complete full ownership of the global Resultz business through the acquisition of the U.S. rights for Resultz,” said Jesse Ledger, Nuvo’s President & CEO.  “We believe the product attributes that have made Resultz a market leader in Canada and Europe, where market capture rates have reached as high as 35%, namely the class-leading 5-minute application time, up to 100% efficacy and exceptional safety profile as a non-pesticide treatment, will make it a success in the United States as well.”

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical investingeuropenuvo pharmaceuticalscanadaunited statesjesse ledger
    The Conversation (0)

    Go Deeper

    AI Powered
    NioCorp Developments Ltd.

    NioCorp Developments Ltd.

    Nova Royalty

    Nova Royalty

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×